159 related articles for article (PubMed ID: 35708076)
1. Capecitabine and Hand-foot Syndrome: A Case Report.
Uppala PK; Varghese AM; Yella SST; Velmurugan H; Thangaraju P; Krishna Sasanka KSBS
Infect Disord Drug Targets; 2023; 23(1):e140622205973. PubMed ID: 35708076
[TBL] [Abstract][Full Text] [Related]
2. Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome.
Santos-Leite ÉGD; Sacramento LV; Santana AM; Dantas JBL; Carrera M; Martins GB
Braz Dent J; 2022; 33(4):97-102. PubMed ID: 36043574
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
Do JE; Kim YC
Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
[TBL] [Abstract][Full Text] [Related]
4. Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.
Azuma Y; Hata K; Sai K; Udagawa R; Hirakawa A; Tohkin M; Ryushima Y; Makino Y; Yokote N; Morikawa N; Fujiwara Y; Saito Y; Yamamoto H
Biol Pharm Bull; 2012; 35(5):717-24. PubMed ID: 22687407
[TBL] [Abstract][Full Text] [Related]
5. Hand-foot syndrome with scleroderma-like change induced by the oral capecitabine: a case report.
Lee SD; Kim HJ; Hwang SJ; Kim YJ; Nam SH; Kim BS
Korean J Intern Med; 2007 Jun; 22(2):109-12. PubMed ID: 17616027
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine-induced oral mucosal hyperpigmentation associated with hand-foot syndrome - A literature review.
Nascimento ADAD; Porto DM; Vidal AKL
An Bras Dermatol; 2023; 98(3):302-309. PubMed ID: 36803558
[TBL] [Abstract][Full Text] [Related]
7. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Narasimhan P; Narasimhan S; Hitti IF; Rachita M
Cutis; 2004 Feb; 73(2):101-6. PubMed ID: 15027515
[TBL] [Abstract][Full Text] [Related]
8. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer.
Vickers MM; Easaw JC
J Gastrointest Cancer; 2008; 39(1-4):141-3. PubMed ID: 19440857
[TBL] [Abstract][Full Text] [Related]
9. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Lassere Y; Hoff P
Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of AboundTM for hand-foot syndrome caused by capecitabine].
Fujii C; Imamura H; Fukunaga M; Kamigaki S; Kimura Y; Kawase T; Kawabata R; Fujino M; Iseki C; Hamaguchi Y; Yamamoto E; Ishizaka T; Hachino Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):2457-9. PubMed ID: 24394143
[TBL] [Abstract][Full Text] [Related]
11. Palmar-plantar erythrodysesthesia associated with capecitabine chemotherapy: a case report.
Kigen G; Busakhala N; Njiru E; Chite F; Loehrer P
Pan Afr Med J; 2015; 21():228. PubMed ID: 26523170
[TBL] [Abstract][Full Text] [Related]
12. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome: A Randomized Phase III Trial of the AIO Quality of Life Working Group.
Hofheinz RD; Gencer D; Schulz H; Stahl M; Hegewisch-Becker S; Loeffler LM; Kronawitter U; Bolz G; Potenberg J; Tauchert F; Al-Batran SE; Schneeweiss A
J Clin Oncol; 2015 Aug; 33(22):2444-9. PubMed ID: 26124485
[TBL] [Abstract][Full Text] [Related]
13. Topical henna ameliorated capecitabine-induced hand-foot syndrome.
Ilyas S; Wasif K; Saif MW
Cutan Ocul Toxicol; 2014 Sep; 33(3):253-5. PubMed ID: 24021017
[TBL] [Abstract][Full Text] [Related]
14. Hand and foot syndrome secondary to capecitabine.
Lal HS
Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
[TBL] [Abstract][Full Text] [Related]
15. [Hand-foot syndrome with capecitabine therapy].
Marini A; Hengge UR
Hautarzt; 2007 Jun; 58(6):532-6. PubMed ID: 16897045
[TBL] [Abstract][Full Text] [Related]
16. Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.
Lou Y; Wang Q; Zheng J; Hu H; Liu L; Hong D; Zeng S
Chem Res Toxicol; 2016 Oct; 29(10):1591-1601. PubMed ID: 27631426
[TBL] [Abstract][Full Text] [Related]
17. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
19. [Breast cancer and the hand-foot syndrome].
Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
[TBL] [Abstract][Full Text] [Related]
20. [Capecitabine-induced hyperpigmentation].
Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
